Patient-as-bioreactor in-body tissue architecture generates autologous multicellular constructs for durable diabetic wound repair

Read full text Summarise with VIRAT
Authors: Ryuji Higashita, Yasuhide Nakayama, Ryosuke Iwai, Marina Funayama‐Iwai, Tomohisa Sakaue
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Chronic diabetic foot ulcers remain refractory to contemporary care, partly because durable repair requires reconstruction of an integrated, multicellular regenerative niche—an outcome rarely achieved without complex ex vivo manufacturing. We advance a patient-as-bioreactor paradigm in which in-body tissue architecture (iBTA) repurposes the body for in vivo manufacturing of autologous multicellular regenerative constructs (“biococktails”) using a temporary subcutaneous device. In a first-in-human exploratory study, 37 devices were successfully implanted, and the primary endpoint—generation of ≥ 1 construct meeting predefined quality criteria—was achieved in all 10 patients. A single application initiated sustained wound repair, reaching a mean 84.15% wound-area reduction at 12 weeks. Reproducible, self-assembled niches enriched for stem cell–associated programs, reparative macrophage signatures, nascent vasculature, extracellular matrix components, and broad regenerative signaling were observed. No amputations or treatment-related serious adverse events occurred. These findings establish iBTA as a scalable, patient-specific in vivo manufacturing platform for multicellular regenerative therapies.

Fields of Study & Subjects

Wound Healing and Treatments Tissue Engineering and Regenerative Medicine Diabetic Foot Ulcer Assessment and Management

Publication details

Journal / source
Research Square
Publication date
23 March 2026
Language
EN
Document type
Preprint